硼替佐米在多发性骨髓瘤患者维持治疗中的疗效观察

发布时间：2018-10-26 10:22

【摘要】：目的:观察以硼替佐米或马法兰为主的化疗方案,在初诊有症状的MM或MP治疗后复发难治性的多发性骨髓瘤(MM)患者维持治疗中的疗效。方法:对本院2008-2013年5年期间MM患者的临床经过及转归进行了回顾性分析。19例初诊有症状的MM(13例),复发难治性的MM患者(6例),以硼替佐米(bortezomib)+地塞米松(Dexamethasone)治疗后进行维持治疗的VD组,17例(初诊有症状的MM),接受马法兰+泼尼松治疗后再进行维持治疗的为MP组,比较两组的疗效。结果:可评估的36例患者,中位随访时间16(1-64)个月,两组患者半年复发率比较差异有统计学意义,VD组19例中半年无1例复发,MP组17例中半年有5例复发(P0.05)。结论:VD作为MM患者维持治疗的方案优于MP方案,而且毒副作用小。
[Abstract]:Objective: to observe the efficacy of bortezomil or Mafang regimen in maintaining the treatment of relapsed multiple myeloma (MM) after initial symptomatic MM or MP treatment. Methods: the clinical course and outcome of MM patients from 2008 to 2013 in our hospital were retrospectively analyzed. There were 19 patients with symptomatic MM (13 cases) and 6 patients with relapsing refractory MM (6 cases). In the VD group treated with bortezomil (bortezomib) dexamethasone (Dexamethasone), 17 cases (the first symptomatic MM), treated with marfarin prednisone followed by maintenance therapy) were treated with MP. The curative effect of the two groups was compared. Results: the median follow-up time was 16 (1-64) months. There was a significant difference in the half year recurrence rate between the two groups. In the VD group, there was no recurrence in 19 cases in half a year. In MP group, 5 cases recurred in half a year (P0.05). Conclusion: VD is superior to MP regimen in maintenance therapy for MM patients, and has little side effect.
【作者单位】：新疆克拉玛依市中心医院血液肿瘤科;中国医学科学院血液病医院;新疆乌鲁木齐市疾病预防控制中心;
【分类号】：R733.3

【相似文献】